264 related articles for article (PubMed ID: 35640549)
21. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
Kuk D; Shoushtari AN; Barker CA; Panageas KS; Munhoz RR; Momtaz P; Ariyan CE; Brady MS; Coit DG; Bogatch K; Callahan MK; Wolchok JD; Carvajal RD; Postow MA
Oncologist; 2016 Jul; 21(7):848-54. PubMed ID: 27286787
[TBL] [Abstract][Full Text] [Related]
22. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.
Li J; Smalley I; Chen Z; Wu JY; Phadke MS; Teer JK; Nguyen T; Karreth FA; Koomen JM; Sarnaik AA; Zager JS; Khushalani NI; Tarhini AA; Sondak VK; Rodriguez PC; Messina JL; Chen YA; Smalley KSM
Clin Cancer Res; 2022 May; 28(10):2131-2146. PubMed ID: 35247927
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Buchbinder EI; Sosman JA; Lawrence DP; McDermott DF; Ramaiya NH; Van den Abbeele AD; Linette GP; Giobbie-Hurder A; Hodi FS
Cancer; 2015 Nov; 121(22):4007-15. PubMed ID: 26264378
[TBL] [Abstract][Full Text] [Related]
24. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.
Woodman SE; Davies MA
Biochem Pharmacol; 2010 Sep; 80(5):568-74. PubMed ID: 20457136
[TBL] [Abstract][Full Text] [Related]
25. Evolving Treatment Approaches to Mucosal Melanoma.
Zhang S; Zhang J; Guo J; Si L; Bai X
Curr Oncol Rep; 2022 Oct; 24(10):1261-1271. PubMed ID: 35511393
[TBL] [Abstract][Full Text] [Related]
26. Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives.
Chacón M; Pfluger Y; Angel M; Waisberg F; Enrico D
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825562
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and Management of Acral Lentiginous Melanoma.
Nakamura Y; Fujisawa Y
Curr Treat Options Oncol; 2018 Jun; 19(8):42. PubMed ID: 29951919
[TBL] [Abstract][Full Text] [Related]
28. Melanoma genomics: a state-of-the-art review of practical clinical applications.
Guhan S; Klebanov N; Tsao H
Br J Dermatol; 2021 Aug; 185(2):272-281. PubMed ID: 34096042
[TBL] [Abstract][Full Text] [Related]
29. Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy.
Huang F; Li J; Wen X; Zhu B; Liu W; Wang J; Jiang H; Ding Y; Li D; Zhang X
Sci Rep; 2022 Jun; 12(1):9559. PubMed ID: 35688842
[TBL] [Abstract][Full Text] [Related]
30. Acral melanoma: clinical advances and hope for the future.
Perez MC; Messina JL; Karapetyan L; Neves RI; Sondak VK
Clin Adv Hematol Oncol; 2023 Aug; 21(8):400-409. PubMed ID: 37530614
[TBL] [Abstract][Full Text] [Related]
31. The pharmacotherapeutic management of nail unit and acral melanomas.
Falotico JM; Lipner SR
Expert Opin Pharmacother; 2022 Aug; 23(11):1273-1289. PubMed ID: 35702037
[TBL] [Abstract][Full Text] [Related]
32. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
Meng D; Carvajal RD
Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
[TBL] [Abstract][Full Text] [Related]
33. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
34. Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes.
Wang M; Banik I; Shain AH; Yeh I; Bastian BC
Genome Med; 2022 Jun; 14(1):65. PubMed ID: 35706047
[TBL] [Abstract][Full Text] [Related]
35. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
Niu HT; Zhou QM; Wang F; Shao Q; Guan YX; Wen XZ; Chen LZ; Feng QS; Li W; Zeng YX; Zhang XS
Pigment Cell Melanoma Res; 2013 Sep; 26(5):646-53. PubMed ID: 23751074
[TBL] [Abstract][Full Text] [Related]
36. Advanced Acral Melanoma Therapies: Current Status and Future Directions.
Zhang Y; Lan S; Wu D
Curr Treat Options Oncol; 2022 Oct; 23(10):1405-1427. PubMed ID: 36125617
[TBL] [Abstract][Full Text] [Related]
37. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
[TBL] [Abstract][Full Text] [Related]
38. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE
Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307
[TBL] [Abstract][Full Text] [Related]
39. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.
Bai X; Mao LL; Chi ZH; Sheng XN; Cui CL; Kong Y; Dai J; Wang X; Li SM; Tang BX; Lian B; Zhou L; Yan XQ; Guo J; Si L
Neoplasma; 2017; 64(4):626-632. PubMed ID: 28485171
[TBL] [Abstract][Full Text] [Related]
40. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
